BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI), a leader in drug development and research instrumentation, announced that non-clinical scientist Brad Gien has joined its Culex® services team. The addition of Gien is part of the company's expanded automated in vivo discovery offerings. Gien comes to BASi from NoAb BioDiscoveries in Ontario, Canada. He has 10 years experience in biomedical research, extensive surgery capability and familiarity with the automated Culex system. "His experience and surgical skills will expand the capability of the BASi PK/PD laboratory in Mt. Vernon, Ind.," says David Hopper, director of toxicology for BASi. "It also will increase our study capacity and help develop a wider selection of small laboratory animal research models." The Culex Automated In Vivo Sampling Services offer investigators a way to increase the amount and type of data gathered in drug discovery experiments. By merging BASi's expertise in instrumentation with its service, BASi will provide clients access to better data to make earlier, more informed decisions about compounds. The goal is to increase efficiency and reduce costs associated with taking new drugs to market. Gien holds a Bachelor of Science degree in neuroscience from the University of Lethbridge, Lethbridge, Alberta. In addition to his previous research experience with NoAb BioDiscoveries, he worked for OSI Pharmaceuticals in Boulder, Colo. About BASi BASi is a drug discovery and development services company providing contract research services and research instruments and supplies to the world's leading pharmaceutical companies and medical research organizations. The company, which is based in the Purdue Research Park of West Lafayette, focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit http://www.BASInc.com for more about BASi. This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.